RxDoctor Payments Data

Maryam Barangi, MD

Internal Medicine · Vista, CANPI 1528626918

Payments from drug & device makers

$766in general payments, 2019–2025

Across 36 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$331
  • Lilly USA, LLC$170
  • Pfizer$111
  • Intra-sana Laboratories$50
  • Novo Nordisk$44
  • Phadia US Inc.$21
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$766100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$766 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$28,808
Medicare patients
88
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$44,208
EliquisApixaban28$33,000
JardianceEmpagliflozin30$31,195
FarxigaDapagliflozin Propanediol37$29,910
SynjardyEmpagliflozin/Metformin Hcl13$7,389
SymbicortBudesonide/Formoterol Fumarate19$4,168
Amlodipine-Valsartan-HctzAmlodipine/Valsartan/Hcthiazid15$3,038
Amlodipine-ValsartanAmlodipine Besylate/Valsartan43$2,907
Albuterol Sulfate HfaAlbuterol Sulfate74$1,715
Mirtazapine26$1,695
Atorvastatin Calcium157$1,579
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,560
Rosuvastatin Calcium95$1,556
Metformin Hcl112$1,291
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine11$1,179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$44$44,20831 claims
AstraZenecaFarxiga, Symbicort$331$34,07956 claims
PfizerEliquis$111$33,00028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →